The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Wider reach for nutraceuticals portfolio in Europe, Turkey and Egypt
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Subscribe To Our Newsletter & Stay Updated
